Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.

ABSTRACT: The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal. Two independent cohorts of cognitively normal adults and amyloid-positive (Aβ⁺) patients with mild cognitive impairment (MCI) or AD-dementia underwent [¹⁸F]AV-1451 PET. Methods for tau tracer quantification included: (i) in vivo Braak staging, (ii) regional uptake

SUBMITTER: Maass A 

PROVIDER: S-EPMC5814575 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature